Orthocell Limited announced it has been granted a further Australian patent for its CelGro® collagen medical device platform for soft tissue regeneration and repair applications. The patent entitled 'Suture-less repair of soft tissue' provides additional important intellectual property to protect the CelGro® product platform. The patent has an expiry date of 12 October 2035. This is the first patent granted in the suture-less repair of tissue patent family. Further patent applications are in progress in all major jurisdictions including US, EU and Japan. Suture-less repair of soft tissue refers to the method of repairing damaged soft tissue without the use of stiches. Suture-less repair has the potential to greatly improve the efficiency and efficacy of surgical procedures by simplifying techniques, reducing surgery time and reduces the risk of additional trauma to soft tissue through the use or sutures. Therefore, Orthocell's patented method of suture-less repair provides surgeons with an alternative to direct suture repair of soft tissue defects within tendons, ligaments and nerves.